熱門資訊> 正文
2025-03-11 08:30
1
公司位列標普全球企業可持續發展評估(CSA)前1%
2
公司連續三年入選標普全球《可持續發展年鑑》
3
引領綠色生物藥發展,技術創新賦能健康未來
上海,
2025年3月11日
全球領先的合同研究、開發和生產(CRDMO)服務公司藥明生物(WuXi Biologics, 2269.HK)宣佈,憑藉2024年在可持續發展領域的卓越表現,公司入選標普全球(S&P Global)《可持續發展年鑑2025》(以下簡稱「年鑑」),並在標普全球企業可持續發展評估(CSA)中位列行業前茅,躋身全球前1%。這是藥明生物連續第三年獲此殊榮。
該《年鑑》基於標普全球CSA,評選出各行業在可持續發展方面表現優異的企業。在2024年CSA評估的7690家企業中,僅有來自62個行業的780家企業脫穎而出,成功入選該《年鑑》。
近年來,藥明生物憑藉在可持續發展領域的持續努力和顯著成就,入選2023年和2024年道瓊斯可持續發展指數(DJSI)。此外,作為聯合國全球契約組織(UNGC)和製藥供應鏈倡議組織(PSCI)成員,藥明生物積極倡導可持續發展的戰略舉措並贏得業界廣泛認可。公司連續兩年獲得明晟(MSCI)最高AAA ESG評級和EcoVadis「鉑金」評級;憑藉領先的綠色生物藥解決方案(Green CRDMO),公司成功入選UNGC 「‘二十年二十佳’企業可持續發展案例」報告;連續五年獲評晨星Sustainalytics ESG「行業最高評級」及「區域最高評級」;躋身CDP水安全「A級榜單」並獲得CDP氣候變化領導力級別評分A-;入選富時社會責任指數系列;入選恆生ESG 50指數,充分彰顯了公司在可持續發展領域的卓越表現。
關於藥明生物
藥明生物(股票代碼:2269.HK)是一家全球領先的合同研究、開發和生產(CRDMO)公司。公司通過開放式、一體化生物製藥能力和技術賦能平臺,提供全方位的端到端服務,幫助合作伙伴發現、開發及生產生物藥,實現從概念到商業化生產的全過程,加速全球生物藥研發進程,降低研發成本,造福病患。
藥明生物在中國、美國、愛爾蘭、德國和新加坡擁有超過12000名員工。通過藥明生物的專業服務團隊,以及先進技術和精深洞見,公司為客户提供高效經濟的生物藥解決方案。截至2024年12月底,藥明生物幫助客户研發和生產的綜合項目高達817個,其中包括21個商業化生產項目(不包括新冠項目)。
藥明生物將環境、社會和治理(ESG)視為業務發展和企業精神的重要組成部分,並致力於成為全球生物藥CRDMO領域的ESG領導者,例如應用更綠色環保的新一代生物製藥技術和能源等引領行業發展。公司成立了由首席執行官領導的ESG委員會,全面落實ESG戰略並踐行可持續性發展承諾。更多信息,請訪問:www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒體關係
PR@wuxibiologics.com
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
1
Ranking in top 1% of S&P Global CSA Score
2
Inclusion in Global Yearbook for third consecutive year
3
Leader in Green CRDMO to drive innovation for a healthier future
Shanghai,
March 11, 2025
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability Yearbook 2025 ("Yearbook") for its strong sustainability performance in 2024. The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level of recognition.
The Yearbook aims to distinguish individual companies — within a range of industries — that have demonstrated strong corporate sustainability, based on their S&P Global 2024 CSA Score. Out of the 7,690 companies assessed in the 2024 CSA, only 780 companies, across 62 industries, were recognized as the top performers and selected for inclusion in Yearbook 2025.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to be once again selected for inclusion in the Yearbook, a reflection of our steadfast dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain.
In the past couple of years, WuXi Biologics has also been named to the 2023 and 2024 Dow Jones Sustainability Indices (DJSI) for its unremitting efforts and notable achievements in promoting sustainable development. In addition, as a participant of United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating and EcoVadis Platinum Medal for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.